Lesson plan
Etrasimod
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. It is taken by mouth. The most common side effects include lymphopenia (low levels of lymphocytes) and headache. Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. Etrasimod was approved for medical use in the United States in October 2023, and in the European Union in February 2024.
Article summary
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis. It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system. It is taken by mouth. The most common side effects include lymphopenia (low levels of lymphocytes) and headache. Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer. Etrasimod was approved for medical use in the United States in October 2023, and in the European Union in February 2024.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.